August 17, 2018 – CAF is pleased to make available slides from many of the presentations given at the 2018 Patient-Family Conference held July 6-8, 2018 in Atlanta, GA. PDFs of the presentations may be accessed by clicking on the links below. Fertility and Pregnancy in Thalassemia Cardiac Monitoring in Thalassemia Chelation Overview Patient Outreach and […]
July 24, 2018 – The Cooley’s Anemia Foundation is accepting applications from individuals with thalassemia for the 2018 CAF ApoPharma Distinguished Scholar Award. The CAF-ApoPharma Distinguished Scholar Award, which was established in 2014, is made possible through a grant from pharmaceutical manufacturer ApoPharma. CAF will award up to two scholarships to a U.S. citizen(s) with […]
July 16, 2018 – The Cooley’s Anemia Foundation is proud to announce three new programs intended to benefit members of the U.S. thalassemia community. These programs are: Support for Significant Travel to Treatment Centers The Cooley’s Anemia Foundation (CAF) is offering limited financial assistance to individuals with thalassemia who live 150 or more miles from […]
May 8, 2018 – In honor of International Thalassemia Day (May 8), the Centers for Disease Control and Prevention (CDC) has posted information about thalassemia on their website and a new profile of CAF Board Member Maria Hadjidemetriou on their website. You can view this page by clicking here . CAF thanks the CDC for their support […]
April 16, 2018 – If you plan to attend the CAF Patient-Family Conference in Atlanta this July 6-8 and would like to undergo a Comprehensive Care Evaluation at the nearby Children’s Healthcare of Atlanta (CHOA) Thalassemia Treatment Center, please call to schedule an appointment: Returning Patients: 404-785-3522 New Patients: 404-785-3519 Note: Both pediatric and adult […]
March 26, 2018 – Registration is now open for CAF’s 2018 Patient-Family Conference! This year’s Conference will be held from July 6-8 at the Westin Atlanta Airport Hotel in Atlanta, GA. The 2018 Patient-Family Conference is a unique opportunity for U.S. individuals with thalassemia and their family members (parents, siblings, spouses, etc.) to meet other […]
January 11, 2018 – La Jolla Pharmaceutical Company has initiated a Phase 2 study to evaluate the effect of LJPC-401 (synthetic human hepcidin) on myocardial iron overload in adult patients with transfusion-dependent beta thalassemia. Hepcidin is a hormone that regulates iron absorption and distribution in the body. Hepcidin prevents excessive iron accumulation in vital organs such […]
August 4, 2017 – CAF is pleased to make available slides from many of the presentations from the 2017 Patient-Family Conference held July 7-9, 2017 in Hyattsville MD. PDFs of the presentations may be accessed by clicking on the links below. Please mark your calendars for July 6-8, 2018, the dates for the 2018 Patient-Family […]
August 1, 2017 – CAF is happy to announce the dates for our 2018 Patient-Family Conference, to be held in Atlanta, Georgia from July 6-8. We will share additional details as they become available. We hope you will be able to join us next year! Update: Register now at www.docbw.com/meet/caf/.
July 19, 2017- The 2017 CAF Patient-Family Conference was a true success, with a record-breaking attendance of over 300 members of the U.S. thalassemia community. This annual Conference provides up-to-date information on thalassemia treatment, and gives members of the thalassemia community an opportunity to get to know each other and share experiences. Browse the gallery […]
